Treatment

Tecentriq 840 mg concentrate for solution for infusion, Vusolimogene oderparepvec clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
"neoBREASTIM": A Phase 2 Study of Atezolizumab plus RP1 oncolytic immunotherapy in the NeoAdjuvant setting of Triple-Negative Breast Cancer (TNBC)
This study is testing new ways to treat a type of breast cancer called Triple Negative Breast Cancer (TNBC) before surgery. It combines two medicines, Tecentriq and Vusolimogene oderparepvec, to see if they are safe and help reduce the amount of cancer. It's an early-stage study.
For: Patients with early-stage Triple Negative Breast Cancer
France